Roshan Kumar is a Senior Director and Head of Exploratory Biology and External Innovation at HiFiBiO Therapeutics, where he works to identify novel disease targets and therapeutic approaches and foster high-impact partnerships and collaborations for the company’s internal pipeline and DIS™ platform. He has been with HiFiBiO since 2014, and has worked extensively on development of the company’s droplet-based microfluidic platform for single B cell screening as well as its pipeline of immunomodulatory antibody therapeutics for the treatment of cancer and autoimmune diseases. Dr. Kumar received his PhD in Biochemistry from the Scripps Research Institute and Bachelor’s degrees in Chemistry and Biology from the California Institute of Technology. His postdoctoral studies were performed at the Whitehead Institute for Biological Research at MIT and the Wyss Institute for Biologically Inspired Engineering at Harvard Medical School, where his research was focused on the study of transcriptional regulatory networks in mammalian systems and on understanding how cellular heterogeneity influences fate decisions in individual pluripotent stem cells.